We conducted a retrospective, laboratory-based, multi-center study referring oncological patients suffering from UTI from January 2015 to December 2019 in Beijing, China. A total of three cancer hospitals participated in the study, including Cancer Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing Chaoyang Sanhuan (SH) Cancer Hospital, and Cancer Hospital of Huanxing (HX) Chaoyang District Beijing. Cancer Hospital, CAMS served as a major tertiary-level referral center and clinic hospital for cancer patients in China. All three hospitals focused on the treatment of solid tumors and lymphoma, and none of them set up a hematological malignancy department other than lymphoma. All urine specimens were transported to the central laboratory (Department of Clinical Microbiology Laboratory, Cancer Hospital, CAMS) within two hours of collection for microbial culture. There are regular shuttle buses between the three hospitals, which can be driven in less than 10 min. The complete medical record was inquired from 2015 to 2019. The prevalence of ESBL UTI was observed for 5 years. Cancer patients older than 18 years who had underlying E. coli, K. pneumoniae, K. oxytoca or P. mirabilis related UTI were included in this study. Benign tumor cases, multi-bacteria UTI cases, episodes without antimicrobial susceptibility results, or complete case information were excluded from this study.
Free full text: Click here